Lupin Q2 Profit Surges 74%, Revenue Up 12.6%

11 Nov 2024 , 10:20 AM

Lupin Ltd, a prominent Mumbai-based pharmaceutical company, reported a 74.1% year-on-year increase in consolidated net profit, reaching ₹852.63 Crore for Q2 FY25, driven by robust sales growth. The company’s Q2 revenue rose 12.6% YoY to ₹5,672.73 Crore, compared to ₹5,038.56 Crore in the same quarter last year.

North American sales were ₹1,971.1 Crore, a 5.6% increase from ₹1,866.6 Crore, representing 36% of Lupin’s global sales. India formulation sales grew by 18.8% YoY, totaling ₹2,009.6 Crore, making up 37% of the company’s global sales.

EBITDA for Q2 stood at ₹1,382.7 Crore, marking a 44.3% rise from ₹958.2 Crore a year ago, with the EBITDA margin improving to 25.2% from 19.4%.

Lupin received approval for 10 Abbreviated New Drug Applications (ANDAs) in the U.S. during the quarter, totaling 431 cumulative filings with 329 approvals by September 30, 2024.

According to Managing Director Nilesh Gupta, Lupin’s Q2 performance reflects strong business momentum across regions, fueled by complex generics in the U.S. and double-digit growth in India. Lupin ranks as the third-largest pharmaceutical player in the U.S. by prescriptions and seventh in the Indian Pharmaceutical Market (IPM).